Head to Head Survey: Myovant Sciences (MYOV) versus The Competition
Myovant Sciences (NYSE: MYOV) is one of 48 public companies in the “Biopharmaceuticals” industry, but how does it compare to its competitors? We will compare Myovant Sciences to related businesses based on the strength of its risk, institutional ownership, valuation, dividends, profitability, analyst recommendations and earnings.
This is a breakdown of recent ratings for Myovant Sciences and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Myovant Sciences Competitors||130||795||1737||59||2.63|
Myovant Sciences presently has a consensus target price of $20.00, suggesting a potential upside of 54.32%. As a group, “Biopharmaceuticals” companies have a potential upside of 15.10%. Given Myovant Sciences’ stronger consensus rating and higher possible upside, research analysts clearly believe Myovant Sciences is more favorable than its competitors.
Valuation & Earnings
This table compares Myovant Sciences and its competitors gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Myovant Sciences||N/A||-$83.44 million||-9.19|
|Myovant Sciences Competitors||$563.95 million||$96.15 million||53.90|
Myovant Sciences’ competitors have higher revenue and earnings than Myovant Sciences. Myovant Sciences is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Insider & Institutional Ownership
79.8% of Myovant Sciences shares are owned by institutional investors. Comparatively, 45.2% of shares of all “Biopharmaceuticals” companies are owned by institutional investors. 2.8% of Myovant Sciences shares are owned by company insiders. Comparatively, 15.4% of shares of all “Biopharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
This table compares Myovant Sciences and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Myovant Sciences Competitors||-13,596.89%||-103.37%||-25.51%|
Myovant Sciences beats its competitors on 6 of the 11 factors compared.
Myovant Sciences Company Profile
Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland. Inhibition of GnRH receptors decreases the release of the gonadotropins, luteinizing hormone, or LH, and follicle-stimulating hormone, or FSH, thereby decreasing the down-stream production of estrogen and progesterone by the ovaries in women and testosterone by the testes in men. It is advancing relugolix for the treatment of heavy menstrual bleeding associated with uterine fibroids, endometriosis-associated pain and prostate cancer. It intends to develop its second product candidate, RVT-602, for the treatment of female infertility as part of assisted reproduction.
Receive News & Stock Ratings for Myovant Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences Ltd. and related stocks with our FREE daily email newsletter.